The ALS Unit of the Hospital Carlos III in Madrid was created by Dr. Jesús Mora in 1990, being the first ALS Unit in Spain. In 2014 this Hospital joined the University Hospital La Paz and since then, both constitute a single institution.
In May 2018 the IMELA (ALS Institute of Madrid) was created with the aim of coordinate the ALS care in the region.
This ALS unit combines the diagnostic and multidisciplinary care for ALS patients with the clinical research focused on cognitive impairment assessment by scales validation and cognitive evoked potentials, quality of life studies, biomarkers and clinical trials with experimental therapies.
Comprehensive multidisciplinary care is provided by a team of neurologists, pychologists and nurses supported by neumologists, nutritionists and palliative care specialists in Hospital or home based. The Rehabilitation team provides motor, respiratory and speech therapies.
The Unit serves to ALS patients living in the Madrid Autonomous Community but also to many patients from other regions of the country. About three hundred patients are usually under treatment.
| ALS Unit at the University Hospital La Paz – Carlos III. Madrid | |
|---|---|
| Foundation year | 1990 |
| Director | Dr. Javier Mascias |
| Principal investigator | Dr. Javier Mascias |
| Contact information | |
|---|---|
| Address | Hospital Carlos III-HULP |
| Contact | Dr. Javier Mascias |
| Phone | +34 914532500 |
| ela.hciii@salud.madrid.org | |
| Website | Visit the website |
Publications
- Jesús S. Mora, Teresa Salas, María Camino Fernández, Víctor Rodríguez-Castillo, Saúl Marín, Delia Chaverri & Francisco Rodríguez-Santos. Spanish adaptation of the Edinburgh cognitive and behavioral amyotrophic lateral sclerosis screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.ISSN: 2167-8421 (Print) 2167-9223 Published online: 06 Dec 2017
- Glycogen synthase kinase-3beta expression and phosphorylation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis. González-Muñoz M, Rodríguez-Mahíllo AI, Gil C, Morán Y, Moneo O, Martínez A, Mora JS: Br J Med & Med Research 2014, 4 (1): 263-71
- Mora JS, Salas T, Fajardo ML, Iváñez L, and Rodríguez-Santos F. Self-perceived emotional functioning of Spanish patients with Amyotrophic lateral sclerosis: a longitudinal study. Frontiers in Psychology 2013 Jan 8; 3:609. doi:10.3389/fpsyg.2012.00609.
- Mora-Pardina J, Dols-Icardo O, Juárez-Rufián A, Cordero-Vázquez P, Rodríguez-Rivera FJ, Guerrero-Sola A, Galán-Dávila L, Mascías-Cadavid J, Hernández-Barral M, Catalina Álvarez I, Paradas-López C, Pascual-Calvet J, Povedano M, Muñoz-Blanco JL, Rojas R, Varona L, Clarimón J, Esteban-Pérez J, García-Redondo A: C9orf72 hexanucleotide repeat study in familial and sporadic ALS Spaniards patients. Amyotrophic Lateral Sclerosis 2012; 13 (S1): xx.
- Rodríguez de Rivera FJ, Oreja Guevara C, Sanz Gallego I, San José Valiente B, Santiago Recuerda A, Gómez Mendieta MA, Arpa J, Díez Tejedor E.. Outcome of patients with amyotrophic lateral sclerosis attending a multidisciplinary care unit. Neurologia. 2011 Oct; 26(8):455-60. doi: 10.1016/j.nrl.2011.01.021.
Restricted information
| Serving population | |
|---|---|
| Serving population | 2.000.000 |
| Patient resources | |
|---|---|
| Population based register | No |
| Clinic based register | Yes |
| Geographically matched controls | No |
Banks
There are no banks for this centre
| Research activities | |
|---|---|
| Clinical management research | Yes |
| Neuro epidemiology | No |
| Neuro physiology | No |
| Neuro imaging | No |
| Neuro psychology | Yes |
| Neuro pathology | No |
| Genomics | No |
| Transcriptomics | Yes |
| Metabolomics | Yes |
Clinical Trials - Industry sponsored
| Name | Type | Patients |
|---|---|---|
| ORARIALS-01. Arimoclomol 2019- | Phase III | |
| AB10015. Masitinib 2013-2017. NCT02588677 | Phase II-III | 106 |
| BENEFIT-ALS. Tirasemtiv 2013-2014. NCT01709149 | Phase II | 24 |
| EMPOWER. Dexpramipexole 2011-2013. NCT01281189 | Phase II | 37 |
| TRO 19622.Olesoxime 2009-2011. NCT00868166 | Phase II-III | 67 |
| ALS-TAL-201 Talampanel 2008-2010. NCT00696332. | Phase II | 52 |
| ONO 2506PO. 2004-2006 NCT00403104 | Phase II | 28 |
| EFC1923 Xaliprodem 1997-1999 | Phase II | 79 |
| RILUZOLE 1993-1995 | Phase III | 36 |
| BCAA (branched chain Aminoacids) 1990-1992 .Ajinomoto Ltd | Phase II | 35 |
| AB19001 (masitinib) | Phase II-III | |
| ADORE (oral edaravone) | Phase III |
Clinical Trials - Investigator initiated
There are no clinical trials for this centre